Ep. 267 Sequencing Therapies in NMIBC Management with Dr. Mark Tyson and Dr. Suzanne Merrill

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor of Urologic Oncology at the University of Utah, and leading urologic oncologists Dr. Mark Tyson from Mayo Clinic Arizona and Dr. Suzanne Merrill from Colorado Urology.
---
This podcast is supported by:
Ferring Pharmaceuticals
https://www.ferring.com/home-classic/people-and-families/uro-uro-oncology/bladder-cancer/
---
SYNPOSIS
The discussion delves into the newest treatment strategies and FDA-approved therapies for non-muscle invasive bladder cancer with an emphasis on BCG-refractory patients. They highlight their approaches to sequencing therapies, the real-world applicability of these treatments, and the impact of patient factors in clinical decision-making. The panel also explores emerging trials and innovative treatment mechanisms, emphasizing the importance of personalized care in oncology.
---
TIMESTAMPS
00:00 - Introduction
05:09 - Challenges and Strategies in Treatment
10:55 - Bladder Sparing Therapies
21:41 - Practical Tips for Therapy Administration
30:39 - Challenges and Considerations in Reinduction
37:05 - Clinical Trials and Future Directions
44:11 - Counseling Patients on Treatment Options
57:36 - Concluding Thoughts and Future Outlook
---
RESOURCES
CORE-008 Clinical Trial
https://www.sciencedirect.com/science/article/abs/pii/S1078143924010147
Legend Clinical Trial:
https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.802
CISTO Study
https://pubmed.ncbi.nlm.nih.gov/37980511/